TBXA2R: Thromboxane A2 receptor
Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation.
- Drugs that act on it: 5
- Approved: 3
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on TBXA2R, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 5
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Boehringer Ingelheim Pharmaceuticals120%
- KARE Biosciences120%
| Picotamide | Approved | — | Small molecule | InhibitorThromboxane A2 receptor inhibitor | 0 |
| Ramatroban | Approved | KARE Biosciences | Small molecule | Antagonist | 0 |
| Seratrodast | Approved | — | Small molecule | Antagonist | 0 |
| Terutroban | Phase 3 | — | Small molecule | Antagonist | 0 |
| Terbogrel | Phase 2 | Boehringer Ingelheim Pharmaceuticals | Small molecule | Antagonist | 0 |
- Bleeding diathesis due to thromboxane synthesis deficiency0.60
- Neurodegenerative disease0.51
- Airway obstruction0.37
- Recurrent thrombophlebitis0.37
- Abnormal platelet aggregation0.30
- Thrombotic disease0.26
- Allergic asthma0.26
- Autoimmune disorder of central nervous system0.20
- Hereditary disease0.19
- Atopic asthma0.19
- COVID-190.19
- Blood platelet disease0.18
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2069, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P21731, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets